<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667315</url>
  </required_header>
  <id_info>
    <org_study_id>Bupivacaine 0,375%</org_study_id>
    <nct_id>NCT01667315</nct_id>
  </id_info>
  <brief_title>Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block</brief_title>
  <official_title>Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of ultrasound in regional anesthesia enables reduction in the local anesthetic
      volume. The present study aimed to determine the minimum effective volume of 0.375%
      bupivacaine with epinephrine for interscalene brachial plexus block for shoulder surgery.
      Following approval by the Research Ethics Committee, patients with a physical condition of I
      or II according to the American Society of Anesthesiologists, between 21 and 65 years old and
      subjected to elective surgery of the shoulder and interscalene brachial plexus block will be
      recruited. The volume of the anesthetic will be determined using a step-up/step-down method
      and based on the outcome of the preceding block. Positive or negative block results in a 1mL
      reduction or increase in volume, respectively. The success of the block is defined as the
      presence of motor block in two muscle groups and the absence of thermal and pain sensations
      in the necessary dermatomes within 30 minutes of the injection. Diaphragmatic paralysis,
      pulmonary function and analgesia will be quantified at 30 minutes, 4 and 6 hours. Data will
      undergo statistical analysis in order to determine minimum effective volume of 0.375%
      bupivacaine and, secondarily, the maximum volume that maintains the diaphragmatic function,
      evaluate diaphragm paralysis and its influence in pulmonary function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum effective volume of 0,375% bupivacaine</measure>
    <time_frame>30 minutes</time_frame>
    <description>Minimum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum 0,375% bupivacaine volume that maintains the diaphragmatic function</measure>
    <time_frame>Before block, 10, 20 and 30 minutes, 4 and 6 hours after</time_frame>
    <description>Maximum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery without diaphragmatic block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <description>Spirometric evaluation of forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diaphragmatic Function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <description>Diaphragmatic movement on ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine 0,375%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0,375%</intervention_name>
    <description>Positive or negative block results in a 1-mL reduction or increase in volume, respectively.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 21 and 65 years

          -  Candidates for an elective surgical intervention on the shoulder with indication for
             anesthesia via brachial plexus block

          -  Physical condition of I or II according to the American Society of Anesthesiologists

          -  Body mass index up to 35 kg.m-2

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease

          -  Cognitive impairment or active psychiatric condition

          -  Infection at the site of the puncture for the block

          -  Coagulopathy

          -  Bupivacaine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Fernando Saldanha de Almeida, MD</last_name>
      <email>luizfsa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcelo Vaz Perez, MD PhD</last_name>
      <email>marcelovazperez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo V Perez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Fernando Saldanha de Almeida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

